Introduction 1
The use of performance-enhancing drugs (PEDs), commonly referred as doping agents, is no longer 2 restricted to sport, but affects also the general population. There is an increasing public-health 3 concern about the widespread misuse of illicit drugs among non-competing amateurs and high-4 school students in several European countries and in the USA 1, 2 . Based on anonymous 5 questionnaires, it has been estimated that the consumers of each country represent about 1% of 6 their respective populations 1 . However, one major problem related to the under-or over-7 interpretation of these estimates is the sparse information coming from reliable studies of PED 8 abuse in healthy subjects. There is a substantial under-reporting of the numerous side effects of 9 doping agents. The long-term consequences of their misuse remain largely unknown, and, on the 10 other hand, the chronic toxicity from past long-term abusers must be considered nowadays a 11 growing public health problem. 12
Apart from their claimed role in athletic performance, PED misuse is also strictly associated with 13 serious adverse effects on health, such as cardiovascular diseases and cancer [3] [4] [5] . Clinical studies 14 demonstrated that acute myocardial infarction is the most common event among PED abusers 6, 7 
15
and that left ventricular hypertrophy may even persist after abuse cessation 8 . The entity of these 16 side effects depends on sex, dose, duration of treatment, fitness condition and on genetic factors. 17
The aim of this review is to analyze the current understanding about the molecular effects of 18 supraphysiological doses of doping agents in healthy biological systems in order to define the 19 molecular sensors of organ/tissue impairment, at both mRNA and protein level, determined by 20 PED misuse. Molecular targets are then discussed in relation to the risk of incidence of specific 21 pathological outcomes. Data concerning the effects of supraphysiological doses of doping agents 22 carried out on unhealthy subjects were not considered in this study. The focus was put on two 23 main categories of doping agents, prohibited by the code of World Anti-Doping Agency (WADA): 24 the anabolic androgenic steroids (AASs), specifically testosterone (T) and its most potent 25 derivative dihydrotestosterone (DHT), and the peptide hormones, specifically the growth hormone 26 (GH) and the insulin-like growth factor-1 (IGF-1). 27 Such an abuse among professional athletes and amateurs is in contrast with well-documented 2 adverse effects associated to AAS consumption: AAS abuse is reported to be strictly associated to 3 risk increase in cardiovascular disease, liver diseases and reproductive system alterations and 4 changes in behaviour [28] [29] [30] [31] [32] [33] . These numerous side-effects as well as the chronic toxicity from past 5 long-term abuse in now middle-aged men must be considered, hence, a growing public health 6
problem. 7
Timing and protocols of assumption are extremely variable and in general consumers assume 8 multiple drugs for a total androgen dose ranging between 10-and 100-fold above physiological 9 concentration 34 . The average physiological level of T and/or DHT in male serum is 10 nM 35 . Several 10 reports define 100 nM as a supraphysiological concentration (see Table S1 ). 11
The improvements in muscle strength observed in response to T administration have been widely 12 described previously 9 and are out of scope of this review. 13
The aim of the present review is to highlight the molecular effects (genes, proteins) mediated by 14 T/DHT administration on different cells/systems and strictly associated to increased risk for human 15 health. 16 
18 19
Growth hormone and Insulin-like Growth factor-1 1 Growth Hormone (GH) is a single-chain polypeptide hormone produced and secreted by anterior 2 pituitary gland 36, 37 . GH secretion is regulated by two hypothalamic factors, the Growth Hormone 3
Relasing Hormone (GHRH) and somatostatin, the first stimulating and the last inhibiting the 4 process 38 . GH secretion takes place in a pulsatile manner with major peaks occurring at the onset 5 of slow-wave sleep and few hours after the meal. Many factors affect GH secretion: gender, age, 6 adiposity, sleep, diet, exercise and other 39 . The levels of circulating hormone are maximal at 7 puberty 39 and decline during adulthood 40 ; in aged men, GH levels are 5-to 20-fold lower than 8 young adults, and they are associated to a reduction in GHRH and an increment in somatostatin 38 . 9
Insuline-like Growth Factor 1 (IGF-1), a peptide hormone and a tissue growth factor, is produced 10 by the liver in response to GH action and circulates at nanomolar concentrations. However, GH 11 modulates IGF-1 production in a paracrine/autocrine fashion in healthy individuals in many other 12 GH-responsive tissues 41, 42 . IGF-1 mediates many of GH actions, included anabolic functions and 13 growth promoting effects, and exhibits mitogenic and insulin-like metabolic activities 42 . There are 14 two isoforms in humans: IGF-1-liver type and IGF1Ec, mainly produced by the skeletal muscle and 15 known as Mechano Growth-Factor 43 . 16
Circulating GH and IGF-1 are associated to GH-and IGF-binding proteins (GHBPs and IGFBPs, 17 respectively), which regulate hormone half-life and receptor interaction [44] [45] [46] . In fact, both 18 hormones activate transduction signaling in target tissues through their membrane receptors: the 19 GH receptor (GHR), a plasma membrane-resident receptor of the cytokine receptor class I 20 superfamily 37 , and the IGF-1 receptor (IGF1R), a tyrosine kinase membrane receptor homologous 21 to oncogenes of tyrosine kinase class, along the insulin receptor (IR) 47 . 22
At cellular level, GH/IGF-1 activate the JAK2-Stat5b, the Akt and the MAPK intracellular signalling 23 pathway, particularly important for GH growth-promoting activity 42, 48 . Both hormones promote 24 proliferation and survival of a wide range of cell types [49] [50] [51] [52] and increase differentiation of cells 25 including myoblasts 53, 54 .
26
IGF-1 level in the serum are stable in healthy individuals and its administration inhibit GH release. 27
Subjects with IGF-1 deficiency shows severe growth and mental retardation 55 ; on the other hand, 28
higher circulating levels of IGF-1, within the physiological range, are associated to better overall 29 survival compared to subjects with lower physiological levels 56 . 30
The GH/IGF-1 complex signaling network regulates growth, development and differentiation in 31 several tissues 38 , and also carbohydrate and lipid metabolism [57] [58] [59] .
Muscles, along with bones, represent the main target tissue of the GH/IGF-1 axis 60 . Acute 1 administration of GH regulates muscle mass and metabolism by switching fuel utilization toward 2 fat oxidation 61 . In fact, GH stimulates lipolysis, both at resting and during physical activity, 3 determining a rise in plasma levels of FA 62, 63 and reducing carbohydrate utilization in healthy and 4 in subjects affected by GH deficiency (GHD) 64, 65 . In GHD, lean body mass and muscle mass are 5 reduced 66 but GH treatment ameliorates muscle protein balance by shifting amino acids from 6 oxidative towards synthetic pathways [67] [68] [69] ; similarly, in healthy subjects, GH supplementation 7 determines anabolic effects, mediated by IGF-1 70, 71 , not only by reducing amino acids oxidation 8 but also increasing protein synthesis 72, 73 . The GH-mediated changes in body protein metabolism is 9 time-dependent with a return to basal protein turn-over within few weeks 74 . 10
The GH/IGF-1 axes contributes also to age-dependent sarcopenia: in muscles, aging is associated 11 to a decrement in IGF1R expression and phosphorylation 75 80 . A recent study conducted on a large population of middle-23 aged healthy subjects showed a significant association between higher fasting serum GH-levels 24 and CVD mortality and morbidity risk in man 81 . Moreover, a positive correlation was also observed 25 between slight increments in circulating IGF-1 and the incidence of prostate and colorectal 26 cancers 42, 82 .
27
In order to define a clear map of the fuzzy network of actions determined by supraphysiological 28 exogenous administration of GH/IGF-1 on human health, we review the current understanding of 29 their molecular effects, considering recent works focused only on supraphysiological treatments
Molecular effects of supraphysiological doses of T and DHT 1 2

Vascular effects 3
Testosterone is a vasoactive hormone that predominantly has vasodilatory actions on several 4 vascular beds 83, 84 in a variety of species [85] [86] [87] [88] [89] . The proposed molecular mechanism, underlying this 5 action, involve either Ca 2+ channels and K + channels 90 . 6
Hoppe and co-authors observed a distinct chronic vs acute supraphysiological T effects on single 7 cardiac T-type Ca 2+ channels from neonatal rat ventricular cardiomyocytes 91 . In particular, the 8 chronic supraphysiological treatment (100 nM and 10 µM for 24-30 h) determined an increase in 9 the whole cell T-type calcium current (I Ca,T ) density and in the beating frequencies, supported by 10 an increased expression of pore-forming subunits Ca V 3.1 and Ca V 3.2, both at protein and mRNA 11 levels. Conversely, the administration of acute supraphysiological doses (10 µM) determined a 12 decrease in the I Ca,T current density. Interestingly, the non-genomic acute administration of T on T-13 In general, the deregulation of calcium homeostasis is often a signal of adverse events and, 27 recently, it has been linked to all cancer hallmarks 95, 96 . Hence, we can speculate that 28 supraphysiological T levels might trigger a detrimental cascade of molecular events in muscle 29 tissues, by interfering with calcium current density, eventually leading to major risks of cancer 30
development. 31
Regarding the effects mediated by T on K + channels regulation, Hoppe and co-authors 97 1 demonstrated a cytoprotective effect of T from ischemic cell death in rat ventricular myocytes. 2
The authors reported that supraphysiological doses of T (10 µM) protected cardiomyocytes 3 against ischemic injury by opening mitoK ATP channels and allowing the oxidation of mitochondrial 4 flavoproteins. Similarly, at supraphysiological concentrations (up to 300 µM), T causes potent and 5 rapid vasorelaxation by activating K ATP channels in the human radial artery 98 and by inhibiting Ca 2+ 6 influx in rat aorta 99 , leading to the hypothesis that T stimulates the K V and K Ca channels in large 7 conductance vessels and, conversely, the K ATP channel, in small resistance vessels 98 . 8
Vasodilation affecting K + -and/or Ca 2+ channels is an endothelium-independent process; on the 9 other hand, this phenomenon can occur also through an endothelium-dependent mechanism that 10 includes the production of endothelium-derived vasoactive peptides. At supraphysiological level, arterial wall to the liver 114 . Likewise, an anti-inflammatory role for T was hypothesized by Corcoran 28 and co-authors 116 : they observed that supraphysiological doses of T significantly reduced the 29 expression of the pro-inflammatory cytokines TNF-α and IL-1β in primary HMDM cell culturesRecently, Wan and co-authors 117 reported that supraphysiological levels of DHT (1 µM) 1 determined a converse effect on human umbilical vein endothelial cells (HUVEC) in presence or 2 absence of lipopolysaccharide (LPS), a powerful bacterial virulence proinflammatory factor. It was 3 observed that, in absence of LPS, DHT induced a significantly downregulation of urocortin (UCN1) 4 mRNA and protein expression through an AR-dependent mechanism; conversely, in presence of 5 LPS, UCN1 mRNA and protein expression increased in HUVEC through an AR-independent 6 mechanism, involving p38/MAPK, ERK1/2 and NF-kB activation. UCN1 is a neuropeptide belonging 7 to the corticotropin-releasing factor (CRF), up-regulated by inflammatory cytokines 118 , and 8 involved in the vascular inflammatory process. Hence, such opposing experimental evidences 9 suggest that supraphysiological DHT levels exert on vascular cells a differential action, based on 10 the inflammatory status: T/DHT administration would not induce inflammation per se, but, it could 11 be able to amplify the pro-inflammatory effect of LPS. Also Annibalini and co-authors confirmed 12 recently that the role on inflammation of sex steroids (T, DHT and E2) is dependent on the 13 inflammatory status of the system under investigation 119 . In fact, they demonstrated that the 14 inflammatory action of TNF-α is magnified by co-administration of supraphysiological doses of T 15 Alzheimer's disease (AD), and the age-related decline of circulating T levels in elderly men 137 . 5
Nowadays, it is clear that T increases neuronal resilience against AD-related injuries and it is used 6 as anti-aging drug 138 , but more studies are needed to define the molecular mechanisms involved 7 and to optimize the hormone therapy 139 . 8
More recently, Imperlini and co-authors found out that chronic supraphysiological DHT treatment 9 (0.7 µg/ml total concentration in three doses) on primary human peripheral blood lymphocytes 10 (PBLs) from male healthy donors, induced an anti-apoptotic effect 7d after the first treatment 140 . 11
In fact, it was observed an over-expression of the pro-survival factor Bcl-2 and a reduced 12 activation of pro-apoptotic caspase-3 in the treated cells compared to the untreated PBLs. Indeed 13 that proteomic study pointed out that the steroid treatment affected the expression profile of 14 more than 30 protein species, half of which were related to apoptosis. Similarly, the same anti-15 apoptotic effect was registered in human PBLs when DHT treatment was associated to a single 16 IGF-1 supraphysiological administration 141 . Such a double treatment mimicks the ability of 17 supraphysiological T treatments in increasing serum IGF-1 levels in healthy young men 142 and 18
indicates that DHT+IGF-1 hyperstimulation affects cell adhesion, migration and survival through 19 both downregulation of cytokines and paxillin signaling-related proteins, and activation of several 20 pathways downstream FAK. 21 
22
Biomarkers of T/DHT doping 23
Supraphysiological doses of T and/or DHT are assumed by athletes and amateurs to enhance sport 24 performance and/or to obtain a better body shape. Up to now it is difficult to find convincing 25 reports describing genomic effects of T/DHT chronic treatment on the health of young sportsmen; 26 sometimes, few gene information can be gained by studies planned with different aims, even if 27 those data need to be confirmed in specific validation assays. But recently, Mancini and co-authors 28 performed a chronic supraphysiological DHT treatment (0.7 µg/ml total concentration in three 29 doses) on human PBLs and analysed the differentially expressed genes by a transcriptomic 30 approach in order to define a putative set of biomarkers of steroid doping 143 . In this study, authors 31 reported that 275 genes (210 up-regulated, 65 down-regulated) were differentially expressed 7 32 days after the first treatment, most of them matching significantly the "Skeletal and Muscular 1 Disorder" category according to the Ingenuity Pathway Analysis database. The most upregulated 2 genes in this dataset were IDO1, CXCL13, CCL1, GZMB, VDR and IL2RA. 
Apoptosis 3
As a growth factor, IGF-1 controls proliferation and differentiation, and protects cells against 4 apoptosis, as demonstrated in several in vitro and in vivo systems 144, 145 . Velazquez and co-authors 5 investigated the effects of physiological and supraphysiological IGF-1 levels on preimplantation 6 bovine embryos, with a particular focus on polycystic ovary syndrome (PCS), characterized by high 7 levels of serum IGF-1. These authors found out that at physiological levels (from 50 to 150 ng/ml), 8 IGF-1 did not affect apoptosis. Conversely, at supraphysiological concentrations (from 950 to 1500 9 ng/ml), IGF-1 induced several biological/biochemical effects: a) increased apoptosis; b) decreased 10 TP53 protein expression; c) increased number of cells and IGF1R protein expression in the inner 11 cell mass (ICM) 145 . Such findings do not correlate with previous studies, where a downregulation 12 of IGF1R was observed in blastocysts or mouse embryos treated with high IGF-1 levels 146-148 . 13
As for anti-apoptotic effects, it has been reported that treatments with 50nM of IGF-1, up to 48 h, 14 increased T cell death-associated gene 51 (TDAG51) expression, at gene and protein level, through 15 activation of IGF-1R and p38 MAPK pathway, in mouse embryo fibroblasts 149 . In particular, authors 16 demonstrated that TDAG51 plays a regulative role in the anti-apoptotic effects of IGF-1. 17
Nevertheless, the anti-apoptotic effects of IGF-1 are dose-and system-dependent. In fact, high 18 IGF-1 levels did not determine any apoptotic effects in human PBLs (Orrù personal 19 communication). In this cell system, 6d after a single IGF-1 hyperstimulation, the MAPK signaling 20 pathway was still active; in particular, p70S6K Tyr229, Tyr389 and Tyr421/Ser424 were found all 21 phosphorylated, thus indicating that the acute in vitro treatment generated several sustained 22 signaling, including those related to protein synthesis processes 150 . Such proteomic study showed 23 also a consistent cytoskeletal reorganization mediated by Stat-1 and an overproduction of 24 cytokines positively related to immune response and inflammation. All together these data 25 indicated that, following IGF-1 hyperdosage, circulating PBLs could be more prone to 26 transendothelial migration 150 . 27
In the same experimental model, an acute supraphysiological IGF-1 treatment determined the 28 overexpression of 102 genes, involved in skeletal muscle disorders, as well as in cell-mediated 29 immunological response 143 . Among these genes, the most upregulated species are fibronectin 1 30 (FN1), involved in cell adhesion and migration processes, including host defense and metastasis 151 , 31 and RAB31, an oncogene key regulator of intracellular membrane trafficking and associated to 32 breast cancer 152, 153 . The transcriptomic approach was also adopted by Mitchell and co-authors 154 1 to evaluate the molecular effects induced by GH abuse in PBLs isolated from male and female 2 recreational athletes. GH treatment (2 mg/inj/die for 8 wks) induced an approximately 2-fold 3 increase in serum IGF-1; RTqPCR validation assays confirmed an upregulation of HSPC159, ITGB3, 4 OLFM4 and TUBB1 genes only in females. 5 6
Cancer 7
The system GH/IGF-1 has been recognized for decades for its role in tumorigenesis and 8 growth 42, 155 . IGF-1 plays a key role in tumour formation and proliferation. Several evidences from 9 both humans and animal models demonstrate a link between GH/IGF-1 levels and cancer risk 155 . 10
Transgenic GH overexpressing mice, characterized by elevated circulating IGF-1 levels, exhibit 11 hepatomegaly due to hypertrophy and hyperplasia 156 . The cellular morphological modifications, 12 so-called pre-neoplastic lesions, observed in the liver of GH overexpressing mice are similar to that exposure to elevated hepatic GH levels in transgenic mice model 158, 159 . In particular, the authors 18 evaluated the mRNA and protein expression and the activation of several signaling mediators and 19 effectors involved in cell growth, proliferation and survival, such as Akt2, NFκB, GSK3β, β-catenin, 20 cyclin D1, cyclin E, c-myc, c-jun and c-fos 158, 159 . These studies indicate that prolonged exposure to 21 GH leads to a liver dysregulation of several oncogenic pathways similar to that observed in many 22 human tumors. 23
24
Biomarkers of GH/IGF-1 doping 25
In the last decade, in order to clarify the doping action of the GH/IGF-1 system, few studies were 26 based on gene doping animal models. 27
In this context, a gene doping model of GH-overexpressing rats has been recently used to evaluate 28 both the molecular effects of GH abuse in healthy animals by using a transcriptome approach and 29 to identify putative biomarkers for the detection of unauthorized GH gene therapy in humans. In 30 particular, a gene expression profile was identified on PBLs from rats subjected to long-term GH 31 gene therapy and sacrificed 24 weeks after the injections 160 . Sixty one genes were founddifferentially expressed in GH gene-treated rats 24 weeks after GH gene therapy. These genes 1 were mainly involved in processes as angiogenesis, oncogenesis, apoptosis, cardiac hypertrophy, 2 immune networks, signaling pathways, adipocytokines, arachidonic acid metabolism, CAMs and 3 cytokine-cytokine receptor interaction. Eight differentially expressed genes were selected as 4 candidate biomarkers for the detection of GH abuse, after RT-qPCR validation experiments. Some 5 of the differentially expressed genes are involved in inflammation and immunity, such as: Pla2g2a, 6 a PLA2 group IIa secreted phospholipase A2 involved in many human diseases, including coronary 7 artery disease, colon cancer and inflammation; Rap1B, a small GTPase involved in the platelet 8 activation; and Nfkbia, the NF-kappa B inhibitor alpha, involved in the inflammatory response 160 . 9
Following the same rationale, Macedo A et al. performed a proteomic study to characterize the 10 molecular effects in transgenic IGF-1 overexpressing mice 161 . By delivering the IGF-1-cDNA into 11 multiple muscles of adult animals using adeno-associated virus (AAV) vectors, the muscle whole-12 proteome changes were analyzed after 15 and 30 days, and they were correlated with 13 morphological and functional modifications. The AAV-IGF-1-injected mice can be properly 14 considered a mouse model of doping, since the measured levels of transduced IGF-1 exceed by 15 more 100-and 10-fold those of the endogenous mouse mRNA and protein, respectively. This 16 supraphysiological condition determined, at morphological and structure levels, a marked muscle 17 hypertrophy, neovascularization and a fiber switch from fast to slow type. These cellular 18 alterations are finely supported by proteomic analysis outputs: in IGF-1-transducted muscles, 19 structural proteins involved in muscle hypetrophy and slow fiber-specific proteins were 20 overexpressed, fast type-ones were underexpressed, and the key proteins controlling energy 21 metabolism were upregulated. In particular, the authors suggest that following IGF-1 delivery, a 22 transition from an anaerobic to an aerobic metabolism might occur in muscles, since some of 23 specific enzymes, belonging to both type of energy metabolisms, are concomitantly induced, but 24 not at the same levels. Such a novelty could have been more convincing if time points longer than 25 30 days would have been considered. 26
Although the clinical effects of supraphysiological IGF-1 treatment are well documented, a 27 comparable production of molecular studies on short-and long-term effects on healthy subjects is 28 still missing. In this field, the published papers are mainly aimed to discover new biomarkers for 29 detecting GH/IGF-1 doping. In this context, the unique data, at molecular level, are restricted to 30 the study of effects on the serum levels of IGFBP; for example, it has been reported that IGFBP-4and IGFBP-5 are increased in healthy adults during one month's treatment with supraphysiological 1
GH doses 162 . 2 3
Many questions still remain to be clarified before accurate and reliable methods for doping 4 detection are found. Certainly, in this field, further studies with a large number of subjects are 5 needed. At moment, a very limited number of studies assess the molecular modifications induced 6 by high doses of GH/IGF-1 over time in healthy in vitro and in vivo systems. However, those 7 studies often describe GH/IGF-1 effects in pathological rather than healthy condition, at 8 physiological and/or pharmacological concentrations, values that are lower compared to the doses 9 assumed by abusers. Despite this, the current understanding of the molecular effects of GH/IGF-1 10 abuse shows that supraphysiological doses affect cell function such as apoptosis and cytoskeletal 11 reorganization, and they have implications on the inflammation response and on the skeletal 12 muscle system (Fig. 2) . 13
15
Future perspective 1 2
The extreme heterogeneity of data published so far, regarding the effects of doping agents on 3 health, mirrors the scanty knowledge of PED administration protocols as well as the sparse 4 information on their biological activity at supraphysiological concentrations. There is still a long 5
way to solve such a puzzling tangle, and in this scenario metabonomics studies can provide the 6 missing piece that will allow to gain complementary information to genomics and proteomics. In 7 fact, metabonomics, as defined by Nicholson in 1999, represents "the quantitative measurement 8 of the time-related multiparametric metabolic response of living systems to patho-physiological 9 stimuli or genetic modification"
163 . This approach uses biofluids (urine, plasma, seminal fluid, 10 cerebrospinal fluid, saliva and others) 164 and is mainly based on NMR spectroscopy and/or mass 11 spectrometry procedures 165 . 12
Over the past few years, metabonomic protocols were also applied to the doping field. Dumas and 13 co-authors were the first to demonstrate the potentiality of metabonomics as a tool for the 14 analysis of metabolic perturbations induced by doping agents 166 ; they revealed the biological 15 signature of AASs in cattle by using NMR spectroscopy, and, in particular, they found out that the 16 urinary biomarkers, at supraphysiological level, are associated to nitrogen and energy metabolism. 
MS. 2
However, the purpose of these early studies was to set up and assess MS-based metabonomic 3 strategies as new screening tools for doping agents abuse, thus demonstrating the feasibility of 4 such approaches 169, 170 .
5
Recently it has been described a semi-automated strategy for the annotation (based on 6 experimental masses and retention times) of metabolites in global fingerprints acquired from 7 untargeted metabonomics approach from tissue samples of bovine treated with AASs 171 ; this 8 implementation, in fact, requires specific softwares and is essential for metabolite identification, 9 thus representing the major challenge for the feasibility of metabonomic approach. 10
The application of metabonomics to the doping in humans is mainly focused on the technological 11 advancements and on the search for the most sensitive protocols serum 172, 173 ; few reports are 12 focused on the potential risk of PED consumption for human health. One example comes from 13
West and co-authors, who assessed the risk of human exposure to endocrine active compounds, 14 such as T, in human germ-like cells (GLCs) 174 . At the highest dose tested (100 µM), all the steroid 15 hormones determined a decrease in intracellular level of amino acids and an increase in 16 metabolites related to cellular energetics and metabolism, such as glucose and lactate. Moreover, 17 a decrement in the degree of fatty acid saturation and in C14-C20 fatty acids was observed; finally, 18 at 100 µM T caused a reduction of cholesterol and cholesterol-derivatives. 19
The low number of metabonomic studies evaluating the molecular effects of doping agents on 20 health is related both to ethical concerns and to the great effort in setting up the experimental 21 design. In fact, to perform a metabonomic investigation, whatever the aim pursued, tools, 22 procedures and methods need to be finely scheduled, ranging from the sample collection and 23 preparation to the generation of metabolic profiles/fingerprints, from the raw data processing to 24 the bioinformatic/statistical analysis for metabolite identification. 25
In the field of doping, a successful experimental design depends on the type of sample (plasma or 26 urine) and on the sample collection from PED abusers and from a control-non doped population. 27
Urine samples are, of course, most feasible and easy to collect rather than plasma, especially in a 28 context of amateur or professional sporting event. However, both types of samples are 29 informative about metabolic changes resulting from doping agents abuse: urine, in fact, is a rich 30 source of hydrophilic metabolites; the plasma composition, on the other hand, is more stable and 31
representative of other kind of molecules.
The sample collection represents a challenging issue in a metabonomic study applied to the 1 analysis of doping agents molecular effects in healthy subjects. In fact, metabolic profiles are 2 influenced by fitness condition besides to sex, food consumption, environmental context as well as 3 by individual genetic profile; as a consequence, the critical step of such experimental designs is 4 related to the definition of exclusion/inclusion criteria for volunteers enrollment in both groups, 5 doped and control. A prerequisite of a good study design is having strong matched-groups in order 6 to observe exclusively doping-dependent phenomena and, hence, to identify putative biomarkers 7 in anti-doping analysis. AASs and growth factors constitute the most popular prohibited substances among abusers, and it 3 is now increasingly frequent to run into administration protocols that mix molecules belonging to 4 both classes. The consequences on human health determined by a short and/or long-term PED 5 misuse are partly known but the molecular mechanisms underlying such adverse events are still 6 unclear, and sometime confounding. Here, we reviewed the supraphysiological effects of T/DHT or 7 GH/IGF-1 on different cellular pathways/functions, and discussed the consequences of both 8 treatments strictly associated to inflammation processes and apoptosis. In general, the growth 9 factors, at supraphysiological concentrations, exert mainly anti-apoptotic and/or pro-inflammatory 10 effects in different biological systems; conversely, the actions produced by hyperandrogenic states 11 are less defined and sometimes confounding. Surely, several endogeneous and exogeneous 12 factors have to be considered in order to clarify the molecular mechanisms responsible for health 13 risk factors related to PED abuse; further investigations, including metabonomic studies, are 14 needed to define new biomarkers related to the emergent issue of doping-related-dysfunctions. 
